Background-Hyperglycemia on admission is associated with increased mortality rates in patients with ST-elevation myocardial infarction (STEMI). However, data regarding the relationship between hyperglycemia and myocardial damage in STEMI are scarce. The aim of this study was to determine the relationship of diabetes mellitus status and hyperglycemia on myocardial damage assessed by cardiovascular magnetic resonance imaging and to evaluate the longterm prognostic significance of hyperglycemia in a high-risk STEMI population. Methods and Results-Glucose levels were determined on admission in 411 consecutive STEMI patients reperfused by primary angioplasty. Patients were categorized on the basis of diabetes mellitus status and admission glucose level. Magnetic resonance imaging was performed for assessment of infarct size and microvascular obstruction. The primary clinical end point was the occurrence of major adverse cardiovascular events at long-term follow-up. STEMI patients with pre-existing diabetes mellitus were at greater risk for major adverse cardiovascular events (32% versus 11%; P<0.001) despite having similar infarct sizes and extent of reperfusion injury than nondiabetic patients. Glycemic status on admission was associated with greater myocardial damage and an increased risk for major adverse cardiovascular events (P<0.001). In nondiabetic patients, the risk of severe myocardial injury started to rise once admission glucose exceeded 7.8 mmol/L, whereas the threshold was higher among patients with diabetes mellitus (≥11.1 mmol/L). Conclusions-The higher mortality rate in diabetic versus nondiabetic STEMI patients is not explained by more pronounced myocardial damage. Hyperglycemia on admission is associated with greater myocardial injury and an increased risk of major adverse cardiovascular events at long-term follow-up. However, hyperglycemia has a stronger relationship to myocardial injury in nondiabetic compared with diabetic patients. (Circ Cardiovasc Imaging. 2013;5:708-718.)
H yperglycemia is common during acute myocardial infarction (MI) with a reported incidence of up to 50% in patients with ST-elevation MI (STEMI). 1, 2 Previous studies have consistently demonstrated that hyperglycemia affects both patients with and without previously recognized diabetes mellitus (DM) and is associated with an increased risk of death and major adverse cardiovascular events (MACE). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, it remains unclear whether elevated glucose levels are a marker of greater illness severity attributable to more extensive cardiac damage or a risk factor with a direct causal relationship to the observed adverse clinical outcomes. Furthermore, it is unclear whether hyperglycemia portends a different risk for MACE in patients with and without recognized DM. A recent meta-analysis reported a more significant association between hyperglycemia and risk of death in nondiabetic subjects. 2 However, most previous studies did not compare the effect of hyperglycemia on adverse outcomes based on patients' DM status or only reported on early mortality. 2, 5, [7] [8] [9] [10] 12, 17 
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Cardiovascular magnetic resonance imaging (CMRI) allows for high-resolution assessment of myocardial necrosis and microvascular damage providing a robust and highly reproducible in vivo tissue characterization in patients with MI. [18] [19] [20] To date, this imaging technique has only been applied in a limited number of patients to assess the relationship between hyperglycemia and myocardial damage in MI. 21, 22 Particularly CMRI data from large unselected, consecutive patient series with evolving STEMI including patients with and without established DM treated by contemporary acute MI management are lacking.
The aim of this study was therefore (1) to determine the relationship of DM status and hyperglycemia on myocardial damage/reperfusion injury assessed by CMRI, (2) to evaluate the long-term prognostic significance of hyperglycemia in an
Glucose Measurements
Blood samples were taken at the time of hospital admission to measure glucose level as part of the routine diagnostic work-up. Preexisting DM was defined as known DM on admission, which was treated by either diet and lifestyle measures alone or the additional use of oral glucose-lowering medication and insulin. Patients were categorized on the basis of DM status and admission glucose level according to the guidelines of the American Diabetes Association 23 : Normoglycemia <7.8 mmol/L, hyperglycemia ≥7.8 to 11.0 mmol/L, and severe hyperglycemia ≥11.1 mmol/L.
Electrocardiographic and Enzymatic Analysis
For electrocardiographic interpretation, the cumulative ST-segment resolution ≈90 minutes after PCI, expressed as the percentage, was calculated by 2 blinded observers as described previously. 24 Plasma samples for creatine kinase were collected on admission and subsequently during the hospitalization every 6 hours for 2 days.
Cardiovascular Magnetic Resonance Imaging
Infarct size and microvascular obstruction (MVO) were determined by CMRI at days 1 to 4 after the index event, as described previously. 19 In brief, imaging was performed on a 1.5-Tesla scanner (Intera CV; Philips, Best, the Netherlands). The left ventricular (LV) function was assessed by a standard steady-state free precession technique. Late enhancement images covering the whole ventricle were acquired ≈15 minutes after intravenous administration of 0.2 mmol/kg bodyweight of gadobutrol (BayerSchering, Berlin, Germany). A 3-dimensional inversion-recovery turbo gradient echo sequence was used for image acquisition.
Off-line image analysis was performed on an independent workstation with dedicated software (ViewForum release 5.2, Philips Medical Systems). All measurements were performed by fully blinded operators at the CMRI core laboratory. Infarct size and MVO were expressed as percentage of LV volume, given by the sum of late enhancement and MVO regions for all slices divided by the sum of the LV myocardial cross-sectional volumes (%LV).
The area of abnormal signal intensity was measured in the late enhancement images by manual delineation in each of the short axis images. In patients with MVO, these dark areas were included for infarct size analysis; and the area of MVO was assessed separately ( Figure 1 ). We assessed late MVO, as recent literature indicates that late MVO might be the strongest predictor of clinical prognosis in STEMI patients. 19 Additionally the MVO/infarct size ratio was calculated for all patients. 25 The CMRI core laboratory has proven excellent reproducibility (mean bias −0.5 %LV, limits of agreement ±2.4 %LV) and low interobserver and intraobserver variability (mean bias 0.3 %LV, limits of agreement ±1.7 %LV and −0.7 %LV, limits of agreement ±2.2 %LV, respectively) for infarct size assessment. 26 
Clinical End Points
The primary end point of this study was the occurrence of MACE, defined as a composite of death, reinfarction, and new congestive heart failure at long-term follow-up. Posthospital follow-up included 1 outpatient visit at 6 months. Long-term follow-up was conducted via telephone contact using a standard questionnaire. In case of any event, these were verified by hospital charts, direct contact with the treating physician, or contact with the local government registration. The follow-up interviewer was not aware of the results of the CMRI studies.
The diagnosis of reinfarction during the index hospitalization was based on clinical symptoms, new ST-segment changes, and an increase in the creatine kinase-myocardial band levels above the reference limits in patients with normalized values or if there was an increase of >20% from the last non-normalized measurement. 27 At follow-up, any new ischemic symptoms leading to hospital admission accompanied by elevated troponin were defined as recurrent MI. New heart failure was defined as congestive heart failure (rales, dyspnea, New York Heart Association functional class III to IV) requiring medical attention and treatment with diuretics occurring >24 hours after the index event.
Statistical Analysis
Each categorical variable is expressed as the number and percentage of patients. Most continuous variables had non-normal distribution and are therefore presented as medians together with interquartile range. Differences between groups were assessed by Fisher exact or the χ 2 test for categorical variables and by 2 sample t tests or 1-way ANOVA tests for continuous data with normal distribution. Otherwise the nonparametric Wilcoxon rank-sum test or Kruskal-Wallis test was used. The Kaplan-Meier method was used to illustrate the timing of events during long-term follow-up; assessment of statistical significance was performed using the log-rank test. Simple Cox regression analysis was used to identify predictors of MACE during long-term follow-up. Significant variables (P<0.05) were then tested in a stepwise multiple Cox regression analysis. We also performed an additional Cox proportional hazards model with glucose level on admission, DM status on admission, as well as their interaction term to test the hypothesis that the prognostic effect of hyperglycemia is different between patients with and without DM. All statistical tests were performed with SPSS software, version 17.0 (SPSS Inc, Chicago, IL). A 2-tailed P<0.05 was considered statistically significant.
Results
Of 498 eligible consecutive STEMI patients who underwent primary PCI, this CMRI study included 411 patients. The main reason for exclusion from the study was the lack of a CMRI examination (n=74) or missing glucose levels on admission (n=13) ( Figure 2 ). The majority of patients (n=323, 79%) did not have a history of DM. Long-term follow-up was available in 401 patients (98%) at a median of 19 months (interquartile range 12-26). Reasons for a lacking long-term follow-up were that 8 participants could not be located (lost to follow-up) and 2 participants withdrew their study participation. There was no difference in follow-up times between diabetic and nondiabetic patients (19 [13-28] versus 18 [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] months; P=0.24).
Baseline and Patient Characteristics
Demographic and clinical characteristics are shown in Table  1 . Overall, 220 patients (54%) were normoglycemic, 135 hyperglycemic (33%), and 56 presented with severely elevated glucose levels ≥11.1 mmol/L (14%) ( Figure 2 ). Patients with known DM (n=88) presented more often with hyperglycemia (42% versus 30%; P=0.08) or glucose levels ≥11.1 mmol/L (40% versus 7%; P<0.001). Consequently, the median glucose value was significantly higher in patients with pre-existing DM compared with patients without a history of DM (Table 1) .
Patients with known DM were older, more likely female, obese or to present with a history of hypertension, hyperlipidemia, or coronary artery disease (P<0.001, respectively). Multivessel disease was also more common in patients with DM. Reperfusion times were similar between groups.
Angiographic Analysis and ST-Segment Resolution
Pre-and postprocedural thrombolysis in MI-flow grades were not significantly different between patients with and without DM. However, a trend regarding an impaired thrombolysis in MI-flow after PCI could be observed in patients with known DM (P=0.07). ST-resolution as a continuous variable was not significantly different in patients without antecedent DM versus those with DM.
Cardiovascular Magnetic Resonance Imaging
The median time between the index event and CMRI was 3 days (interquartile range 2-4). Infarct size and LV ejection fraction were similar between nondiabetic patients versus patients with DM. MVO was identified in 243 patients (59%) with similar occurrence and extent in patients without known DM versus those with DM ( Table 2 ). However, patients with known DM had a significantly higher MVO/infarct size ratio as compared with nondiabetic patients (P=0.03).
In the overall study cohort, there was a graded relationship between glycemic status on admission and infarct size, more reduced LV ejection fraction and the presence and extent of MVO (P<0.001, respectively, Figure 3A -3C). Within the group of patients without known DM, such a stepwise relationship between glycemic status on admission and infarct size, LV ejection fraction as well as MVO could also be observed (Figure 4 A-4C). In diabetic patients, however, patients with normoglycemia and hyperglycemia had similar myocardial (23) 62 (19) 35 (17) 22 (22) 5 (24) 32 (36) 3 (19) 15 (41) 14 (40) 0.002
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Gp IIb/IIIa receptor inhibitor damage, whereas only patients with severe hyperglycemia ≥11.1 mmol/L on admission had larger infarcts, lower LV ejection fraction, and more pronounced MVO compared with the 2 other groups ( Figure 4A-4C ).
Clinical Outcome
Overall, the combined end point occurred in 65 patients at long-term follow-up with a significantly higher MACE rate in patients with pre-existing DM (28 [32%] versus 37 [11%], hazard ratio 3.2 [CI, 1.9-5.3]; Figure 5A ). In the group of patients with DM 10 deaths (11%) occurred, as opposed to 14 Figure 5B ). In patients without DM this graded relationship was also present (9% versus 12% versus 30%; hazard ratio, 2.2 [CI 1.6-2.9], P=0.007, Figure 5C ). In patients with pre-existing DM, the occurrence of MACE was only significantly higher in patients with severely elevated glucose levels ≥11.1 mmol/L on admission as compared with the 2 other groups (21% versus 21% versus 47%; hazard ratio, 1.9 [CI, 1.1-3.4]; P=0.05, Figure 5D ).
In addition to glycemic status and presence of DM on admission, several established markers of increased patient risk were associated with increased long-term MACE by simple Cox regression analysis ( Table 3 ). The presence of DM remained a significant predictor of MACE even after adjustment of age (hazard ratio, 2.8 [CI, 1.7-4.7]; P<0.001) Table 3) .
To assess a potential difference in the relationship between glucose level and clinical outcome for patients with or without DM, we calculated an interaction term (glucose level×DM status). This interaction term was a significant unadjusted predictor of MACE in our Cox regression analysis, but was not able to independently predict MACE in our multivariable model (data not shown). Therefore, a differential impact of hyperglycemia on clinical events in patients with and without known DM is not supported by our interaction term analysis.
Discussion
This largest CMRI study to date evaluating the relationship of DM status and elevated glucose levels on admission on myocardial damage in patients with STEMI has 3 essential findings: (1) STEMI patients with pre-existing DM are at greater risk for MACE despite having similar infarct sizes and extent of reperfusion injury than patients without known DM; (2) elevated glucose levels on admission are associated with greater myocardial damage (larger infarcts, more pronounced reperfusion injury, LV dysfunction) and an increased risk for Of our CMRI variables listed in Table 2 we only included the MVO/infarct size to avoid collinearity. The MVO/IS ratio was the strongest univariable CMRI predictor of MACE and has MVO and infarct size accounted for by its inclusion in the formula for the calculation.
MACE;
(3) hyperglycemia is a stronger indicator of myocardial injury in STEMI patients without previously recognized DM than in those with established DM.
Thus, this study confirms and expands previous findings by demonstrating that the amount of myocardial injury does not explain the substantially higher mortality rates in diabetic patients with STEMI. Moreover, we could demonstrate that the relationship between hyperglycemia and myocardial damage is different in STEMI patients with and without known DM.
Presence of DM and Myocardial Damage
Similar to previous studies we found that diabetic patients presenting with STEMI have a substantially greater incidence of MACE compared with nondiabetic subjects. 17, 28 Infarct size and the extent of reperfusion injury after PCI are major determinants of poor outcome in patients with STEMI and it has been speculated that these prognostic markers are related to the worse prognosis in patients with DM. Recent studies mainly used enzymatic methods or single photon emission computed tomography for assessment of infarct size in paients with and without DM. The majority of these studies have shown similar or smaller infarct size in diabetic patients. [29] [30] [31] The use of these techniques, however, has several limitations and CMRI has emerged as the reference method for high-resolution assessment of LV function, infarct size, and MVO. 18, 20, 32 In accordance with previous studies, we did not reveal significant differences in infarct characteristics (infarct size, MVO, LV ejection fraction) in diabetics versus nondiabetic STEMI patients. [29] [30] [31] Recently, Mather et al 21 performed the first study that applied CMRI in 92 STEMI patients to determine significant differences in infarct size between nondiabetic and diabetic subjects. The results of this study suggested that patients with DM sustain larger infarctions than normoglycemic or dysglycemic nondiabetic patients, but were limited by the small sample size (only 22 patients with DM included) and reperfusion with thrombolysis. In contrast, our study in STEMI patients treated by primary PCI indicates that the amount of myocardial damage does not explain the higher mortality rates in patients with DM with STEMI. Instead, the relation of severe microvascular injury (MVO) to the extent of infarct expansion (MVO/ infarct size) seems to be a major determinant of prognosis in diabetic patients. MVO/infarct size is a more powerful predictor for long-term outcome after STEMI than either parameter alone reflecting a broader degree of myocardial injury. 25 The extent of infarct size and the development of MVO are influenced by diverging parameters, because MVO is known to be associated with factors beyond the ischemic damage itself, such as reperfusion injury. 19, 25 Our data therefore emphasize the importance of reperfusion strategies in diabetic patients aiming at a reduction of infarct size and preserving microvascular function, such as thrombectomy. However, further studies are necessary to explore the mechanisms that contribute to adverse outcomes in diabetic patients to develop effective therapies for this important high-risk group.
Hyperglycemia and Clinical Outcome in STEMI
The association between elevated glucose levels on admission and adverse clinical outcomes has been a focus of growing attention in patients with MI. Numerous studies have shown that elevated glucose levels are associated with an increased risk of death or cardiovascular complications in patients both with and without known DM. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, many of these studies were limited by the inclusion of selective patient cohorts, patients reperfused by thrombolysis or short follow-up periods. Our data set is one of the few studies that directly compared the relationship between hyperglycemia and long-term clinical outcome in patients with and without previously known DM across the full spectrum of glucose values. Confirming previous studies, hyperglycemia on admission was a common finding in nondiabetic (48%) as well as diabetic (38%) patients with STEMI and higher admission glucose levels were associated with adverse outcomes. However, the risk for clinical events differed between patients with and without known DM. In patients without previously recognized DM, the risk of MACE started to rise once admission glucose exceeded 7.8 mmol/L, whereas the threshold was higher among DM patients (≥11.1 mmol/L). The pathophysiological mechanisms behind the interaction between glucose, adverse outcomes, and diabetes status are not well understood. The use of CMRI in the current study allowed us to obtain further insights into the pathophysiology of this phenomenon. Our CMRI results demonstrate that even mildly elevated glucose seems to be a stronger indicator of myocardial damage (larger infarcts, more pronounced reperfusion injury, more reduced LV ejection fraction) in patients without DM compared with those with DM. Possible explanations for this detrimental effect of hyperglycemia on myocardial damage especially in nondiabetic patients are that (1) hyperglycemic STEMI patients without known DM are less likely to be treated with insulin than patients with known DM, resulting in severely elevated glucose levels with adverse effects on ischemic myocardium; (2) some hyperglycemic patients without known DM likely have DM that was not recognized and treated before hospitalization, therefore representing a high-risk cohort; (3) a higher degree of myocardial damage is required to produce a similar degree of hyperglycemia in patients without pre-existing DM than in those with DM.
Nevertheless, the observed differences in myocardial damage and reperfusion injury may be the reason for the diverging effect of hyperglycemia on adverse outcomes in patients with and without known DM that have been reported in previous studies. 2, 9 However, in our interaction term analysis we did not observe a significant difference in the relationship between glucose level and outcome depending on whether the patient had DM or not.
Thus far, it remains controversial whether acute hyperglycemia predisposes to adverse outcome or is simply a consequence of increased sympathetic and catecholamine response to a large infarct size, thereby reflecting greater disease severity. Recent experimental studies have suggested that hyperglycemia may have a direct detrimental effect on ischemic myocardium. Glucose can induce reactive oxygen species generation resulting in increased oxidative stress and subsequent myocardial injury. 33 Furthermore, hyperglycemia is associated with higher free fatty acid concentrations, insulin resistance, and impaired myocardial glucose use, thus increasing the consumption of oxygen and potentially worsening ischemia. 34 Hyperglycemia also influences coagulation, as it is associated with increased platelet aggregation as well as circulating clotting factors and is associated with increased markers of vascular inflammation. 35, 36 Finally, consistent with our findings microvascular dysfunction and the no-reflow phenomenon were demonstrated in hyperglycemic patients with infarction undergoing reperfusion. 37 These considerations and the results of our study suggest that blood glucose would be an important treatment target to limit the deleterious effect of increased blood glucose in the setting of acute myocardial ischemia. However, specific strategies targeting blood glucose control in STEMI patients have been disappointing. 38, 39 Further well-designed, randomized studies are therefore needed to determine glucose control targets, and a potential clinical effect of glucose control in STEMI.
Limitations
The results of our study should be interpreted in the context of several limitations. First, our results are based on relatively small patient numbers, despite being the largest CMRI study to date assessing the effect of diabetic status and elevated glucose levels on myocardial damage. Second, a significant portion of patients were excluded from the study, mainly because of a lacking CMRI exam. The exclusion of potentially sicker diabetic patients could possibly influence our study results. However, as the number of excluded diabetic patients was small, a potential bias is limited. Third, hyperglycemia was based on a single measurement after hospital admission and thus was not indicative of overall hyperglycemia throughout the hospitalization. Finally, DM was defined as known diabetic status on admission based on clinical history and antidiabetic medication. It is well known that a number of STEMI patients have undetected DM on admission. Furthermore, it is conceivable that some subjects within the nondiabetic group may have progressed to overt DM within the follow-up period. Measurement of hemoglobin A1c as an indicator of long-term glycometabolic derangement might be helpful to distinguish between hyperglycemia in patients with and without DM, but was not performed in the current study.
Conclusions
The substantially higher MACE rate in diabetic versus nondiabetic patients is not explained by more pronounced myocardial damage as assessed by CMRI. Elevated glucose levels on admission are associated with greater myocardial damage and an increased risk of clinical events at long-term follow-up in STEMI patients treated by primary PCI. However, hyperglycemia has a stronger relationship with myocardial injury in patients without previously recognized DM as compared with those with established DM.
